secwatch.observer — SEC 8-K summary
======================================

Issuer:     Stoke Therapeutics, Inc. (STOK)
CIK:        0001623526
Form:       8-K
Filed at:   2024-08-07T23:59:59+00:00
Accession:  0000950170-24-092268
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Stoke Therapeutics Q2 net loss $25.7M; FDA lifts partial clinical hold on zorevunersen
--------------------------------------------------------------------------------

- FDA removed Partial Clinical Hold on zorevunersen for Dravet syndrome; planning Phase 3 registrational study.
- Q2 revenue $4.8M (vs. -$2.5M prior year); net loss $25.7M ($0.46/shr) vs. $30.7M ($0.69/shr) prior year.
- Cash, cash equivalents, and marketable securities totaled $282M as of June 30, 2024.
- On track to initiate Phase 1 OSPREY study of STK-002 for Autosomal Dominant Optic Atrophy in 2024.
- Regulatory discussions ongoing; update on Phase 3 registrational plans for zorevunersen expected H2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1623526/000095017024092268/0000950170-24-092268-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1623526/000095017024092268/stok-20240807.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-092268

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer